Company NFL Biosciences

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Market Closed - Euronext Paris 16:55:00 22/10/2026 BST			5-day change	1st Jan Change
0.5600 ^EUR	+1.82%		-3.11%	-52.46%

11:24am	NFL Biosciences Gets Regulatory Approvals to Begin Phase 2 Nicotine Cessation Trial for NFL-102	MT
11:05am	Nfl Biosciences Receives Regulatory Approval to Begin Its Phase 2 Tonic Study Evaluating Nfl-102 for Smoking and Nicotine Cessation	CI

Business description: NFL Biosciences

NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents.

At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Number of employees: 4

Sales by Activity: NFL Biosciences

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Biotechnology (Startups)	39	22	200K	46	188

See all business segments

Geographical breakdown of sales: NFL Biosciences

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
France	39	22	200K	46	188

See all geographic segments

Executive Committee: NFL Biosciences

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	16/10/2024
Guillaume Audema DFI	Director of Finance/CFO	-	31/12/2021
Yannick Plétan CTO	Chief Tech/Sci/R&D Officer	-	16/10/2024
Ignacio Faus CEO	Chief Executive Officer	-	18/05/2021
Lara Babich PRN	Corporate Officer/Principal	-	31/12/2023

See NFL BIOSCIENCES governance

Composition of the Board of Directors: NFL Biosciences

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	26/02/2023
Bruno Lafont CHM	Chairman	-	16/10/2024
Francis Ahner BRD	Director/Board Member	-	18/05/2021
Yannick Plétan BRD	Director/Board Member	-	18/05/2021
Dominique Côté BRD	Director/Board Member	-	31/05/2023

Composition of the Board of Directors

Shareholders: NFL Biosciences

Name	Stocks	%	Valuation
Friedland Gestion SAS 0.1609 %	20,395	0.1609 %	15 984 €

List of NFL BIOSCIENCES shareholders

Company details: NFL Biosciences

NFL Biosciences SAS

199, rue Hélène Boucher

34170, Castelnau-le-Lez

+33 4 11 93 76 67

http://www.nflbiosciences.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	+1.82%	-3.11%	-52.14%	-50.44%	7.82M
WUXI APPTEC CO., LTD.	-4.10%	-8.35%	+38.48%	+66.99%	66.22B
ARGENX SE	-0.41%	+3.27%	+10.46%	+73.74%	55.2B
LONZA GROUP AG	+0.74%	+4.04%	+12.18%	+91.76%	52.79B
IQVIA HOLDINGS INC.	-0.43%	+1.08%	+25.76%	+49.13%	45.53B
BEONE MEDICINES AG	-1.50%	+1.86%	+21.53%	+125.83%	43.94B
REVOLUTION MEDICINES, INC.	-3.73%	-1.13%	+253.19%	+919.45%	41.64B
CELLTRION, INC.	-1.67%	+8.06%	+14.17%	+56.67%	34B
WUXI BIOLOGICS (CAYMAN) INC.	-8.38%	-9.01%	+25.65%	-1.82%	25.84B
GENMAB A/S	+1.30%	+4.94%	+38.23%	+28.03%	23.51B
Average	-1.61%	+2.52%	+38.75%	+135.93%	38.87B
Weighted average by Cap.	-1.86%	+3.43%	+47.53%	+159.37%